GlassScriptPhysician profile
Margaret C Siman
NPI 1225006729
$3,144.72
in general payments reported to CMS, 2019-2025
22 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $451 · 2021: $552 · 2022: $533 · 2023: $652 · 2024: $320 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $792.64 | 2019-2025 | |
| Lilly USA, LLC | $607.36 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $423.13 | 2019-2022 | |
| Novo Nordisk INC | $295.60 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $231.74 | 2021-2024 | Farxiga, Lokelma, Breztri |
| Otsuka America Pharmaceutical, INC. | $205.89 | 2022-2025 | Rexulti |
| Abbvie INC. | $109.60 | 2022-2023 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $106.96 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $63.87 | 2022-2023 | |
| Amgen INC. | $37.45 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.36 | 2022 | |
| Neuronetics, INC. | $30.59 | 2025 | Neurostar Tms Therapy System |
| Abbott Laboratories | $29.66 | 2021-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $27.89 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.27 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.02 | 2023 | Gemtesa |
| Cashflow Solutions, LLC | $18.99 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.21 | 2024 | Fanapt |
| Astellas Pharma US INC | $17.96 | 2024 | Veozah |
| Exact Sciences Corporation | $17.61 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $16.41 | 2022 | |
| Merck Sharp & Dohme LLC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Siman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.